Novartis cues up Cosentyx as disease-modifying treatment for psoriasis
auto-immune diseases, Celgene, Eli Lilly, Johnson & Johnson, Novartis, psoriasis
0 Comment
Pharma begins early intervention trial after Cosentyx shows “disease modifying” properties